In vitro dose comparison of Respimat^® inhaler with dry powder inhalers for COPD maintenance therapy

References

• FinlayWHThe mechanics of inhaled pharmaceutical aerosolsSan Diego, CAAcademic Press Inc2001
   Google Scholar
• JohnstoneAUddinMPollardAHeenanAFinlayWHThe flow inside an idealised form of the human extra-thoracic airwayExperiments Fluids2004375673689
   Web of Science ®Google Scholar
• OlssonBBorgstromLLundbackHSvenssonMValidation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation productsJ Aerosol Med Pulm Drug Deliv201326635536923421897
   PubMed Web of Science ®Google Scholar
• WachtelHBickmannDBreitkreutzJLangguthPCan pediatric throat models and air flow profiles improve our dose finding strategy?Paper presented at: Respiratory Drug DeliveryApril 25–29, 2010Orlando, Florida, USA
   Google Scholar
• WachtelHFlügeTGösslRFlow – pressure – energy – power: which is the essential factor in breathing patterns of patients using inhalers?Paper presented at: Respiratory Drug DeliveryApril 23–27, 2006Boca Raton, Florida, USA
   Google Scholar
• Global Strategy for Diagnosis, Management, and Prevention of COPD2005 Available from: http://www.goldcopd.orgAccessed December 1, 2005
   Google Scholar
• HorsfieldKCummingGMorphology of the bronchial tree in manJ Appl Physiol19682433733835640724
   PubMed Web of Science ®Google Scholar
• RaabeOYehHSchumGPhalenRTracheobronchial geometry: human, dog, rat, hamster – a compilation of selected data from the project respiratory tract deposition modelsU.S. Energy Research and Development Administration, Division of Biomedical and Environmental Research1976
   Google Scholar
• Haefeli-BleuerBWeibelERMorphometry of the human pulmonary acinusAnat Rec198822044014143382030
   PubMedGoogle Scholar
• FinlayWHLangeCFKingMSpeertDPLung delivery of aerosolized dextranAm J Respir Crit Care Med20001611919710619803
   PubMed Web of Science ®Google Scholar
• TianGLongestPWSuGHindleMCharacterization of respiratory drug delivery with enhanced condensational growth using an individual path model of the entire tracheobronchial airwaysAnn Biomed Eng20113931136115321152983
   PubMed Web of Science ®Google Scholar
• Mead-HunterRKingAJCLarcombeANMullinsBJThe influence of moving walls on respiratory aerosol deposition modellingJ Aerosol Sci2013644859
   Web of Science ®Google Scholar
• WeibelERMorphometry of the human lung: the state of the art after two decadesBull Eur Physiopathol Respir1979155s999s1013
   Google Scholar
• LongestPWVinchurkaSValidating CFD predictions of respiratory aerosol deposition: effects of upstream transition and turbulenceJ Biomech200740230531616533511
   PubMed Web of Science ®Google Scholar
• LongestPWHolbrookLTIn silico models of aerosol delivery to the respiratory tract – Development and applicationsAdv Drug Deliv Revs201264429631121640772
   PubMed Web of Science ®Google Scholar
• BarnesPJDistribution of receptor targets in the lungProc Am Thorac Soc20041434535116113456
   PubMedGoogle Scholar
• MakJCBarnesPJAutoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lungAm Rev Respir Disss1990141615591568
   Web of Science ®Google Scholar
• IkedaTAnisuzzamanASYoshikiHRegional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airwaysBr J Pharmacol201216661804181422300233
   PubMed Web of Science ®Google Scholar
• De BackerJWVosWGVinchurkarSCValidation of computational fluid dynamics in CT-based airway models with SPECT/CTRadiology2010257385486221084417
   PubMed Web of Science ®Google Scholar
• BarnesPJBasbaumCBNadelJAAutoradiographic localization of autonomic receptors in airway smooth muscle. Marked differences between large and small airwaysAm Rev Respir Dis198312767587626305241
   PubMed Web of Science ®Google Scholar
• van KoppenCJRodrigues de MirandaJFBeldAJHermanussenMWLammersJWJvan GinnekenCAsCharacterization of the muscarinic receptor in human tracheal smooth muscleNaunyn Schmiedeberg’s Arch Pharmacol19853312–32472523911071
   PubMedGoogle Scholar
• ZankerDCuoghiESinghDEhlichHSommererKJauernigJIn Vitro Dose Delivery Performance of Glycopyrronium using Representative Inspiratory Flow Profiles derived from COPD PatientsPaper presented at: Drug Delivery to the LungsDecember 5–7, 2012Edinburgh, UK
   Google Scholar
• MaggioRMVignaduzzoSEKaufmanTSPractical and regulatory considerations for stability-indicating methods for the assay of bulk drugs and drug formulationsTrends Anal Chem2013495770
   Web of Science ®Google Scholar
• VoshaarTAppEMBerdelDArbeitsgruppe Aerosolmedizin der Deutschen Gesellschaft für PneumologieRecommendations for the choice of inhalatory systems for drug prescriptionPneumologie20015512579586 German11748508
   PubMedGoogle Scholar
• KuttlerADimkeTA Novel biophysical simulation model of drug deposition implemented to predict and optimize Qva149 delivery to the lungsSan Diego: Paper presented at: ATS2014
   Google Scholar
• MagnussenHWatzHZimmermannIPeak inspiratory flow through the Genuair-inhaler in patients with moderate or severe COPDRespir Med2009103121832183719651504
   PubMed Web of Science ®Google Scholar
• WedaMZanenPBoerAHBarendsDMFrijlinkHWAn investigation into the predictive value of cascade impactor results for side effects of inhaled salbutamolInt J Pharmaceutics20042871–27987
   Web of Science ®Google Scholar
• HowarthPHWhy particle size should affect clinical response to inhaled therapyJ Aerosol Med200114Suppl 1S27S3411424890
   PubMedGoogle Scholar
• WilsonAJMurphyCMBrookBSBreenDMilesAWTilleyDGA computer model of the artificially ventilated human respiratory system in adult intensive careMed Eng Phys20093191118113319699134
   PubMed Web of Science ®Google Scholar
• OldhamMJPhalenRFHeistracherTComputational fluid dynamic predictions and experimental results for particle deposition in an airway modelAerosol Sci Technol20003216171
   Web of Science ®Google Scholar
• BrandPHedererBAustenGDewberryHMeyerTHigher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor techniqueInt J COPD200834763770
   Google Scholar
• BrandPHedererBLoeweLHerpichSHaeussermannSSommerKFlow dependency of lung deposition after inhalation with a HFA-pMDI and the Respimat® Soft Inhaler in COPD patientsPneumologie200761127
   Google Scholar
• NewmanSPSteedKPReaderSJHooperGZierenbergBEfficient delivery to the lungs of flunisolide aerosol from a new portable handheld multidose nebulizerJ Pharm Sci19968599609648877887
   PubMed Web of Science ®Google Scholar
• NewmanSPSuttonDJSegarraRLamarcaRDe MiquelGLung deposition of aclidinium bromide from Genuair, a multidose dry powder inhalerRespiration200978332232819451700
   PubMed Web of Science ®Google Scholar
• StewartJICrinerGJThe small airways in chronic obstructive pulmonary disease: pathology and effects on disease progression and survivalCurr Opin Pulm Med201319210911523325030
   PubMed Web of Science ®Google Scholar
• BalashazyIHofmannWDeposition of aerosols in asymmetric airway bifurcationsJ Aerosol Sci1995262273292
   Web of Science ®Google Scholar
• BorghardtJMWeberBStaabAKunzCSchieweJKloftCExpanding the mechanistic knowledge about pulmonary absorption processes using a population pharmacokinetic model for inhaled olodaterolPaper presented at: Respiratory Drug DeliveryMay 4–8, 2014Fajardo, Puerto Rico, USA
   Google Scholar
• CicilianiAMLangguthPBickmannDWachtelHVoshaarTIn vitro dose comparison of respimat soft mist inhaler with dry powder inhalers for copd maintenance therapyPaper presented at: 19th ISAM CongressApril 6–10; 2013Chapel Hill, North Carolina, USA
   Google Scholar
• CicilianiAMWachtelHLangguthPRespimat soft mist inhaler shows higher in vitro deposition performance compared to other copd inhalersPaper presented at: 20th ISAM CongressMay 30–June 3; 2015Munich, Germany
   Google Scholar
• CicilianiAMWachtelHLangguthPRespimat soft mist inhaler shows higher in vitro deposition performance compared to other copd inhalersJ Aerosol Med Pulm Drug Deliv2015283A33A33
   Web of Science ®Google Scholar
• Spiriva Respimat OKed for COPD in Europe thepharmaletter2007 Available from: http://www.thepharmaletter.com/article/spiriva-respimat-oked-for-copd-in-europeAccessed November 29, 2016
   Google Scholar
• Asthma: new indication for Spiriva^® (tiotropium) Respimat^®* in the EUBoehringer Ingelheim press release; 2014 Available from: https://www.boehringer-ingelheim.com/press-release/asthma-new-indication-spiriva-tiotropium-respimat-eu-may-offer-millions-adultsAccessed December 3, 2016
   Google Scholar
• Seebri Breezhaler. Summary for the Public2012 Available from: http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Summary_for_the_public/human/002430/WC500133772.pdfAccessed July 12, 2015
   Google Scholar
• Eklira Genuair. Summary for the public2013 Available from: http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Summary_for_the_public/human/002211/WC500132664.pdfAccessed July 12, 2015
   Google Scholar
• RELVAR^® ELLIPTA^® receives European marketing authorisation for the treatment of asthma and COPDGSK press release; 2013 Available from: http://www.gsk.com/en-gb/media/press-releases/2013/relvar-ellipta-receives-european-marketing-authorisation-for-the-treatment-of-asthma-and-copd/Accessed November 11, 2016
   Google Scholar
• FDA Approves Anoro Ellipta Drugs.com2013 Available from: http://www.drugs.com/newdrugs/fda-approves-anoro-ellipta-chronic-obstructive-pulmonary-3992.htmlAccessed February 19, 2015
   Google Scholar
• GSK receives approval for Incruse™ Ellipta^® (umeclidinium) in the US for the treatment of COPDGSK press release; 2014 Available from: http://us.gsk.com/en-us/media/press-releases/2014/gsk-receives-approval-for-incruse-ellipta-umeclidinium-in-the-us-for-the-treatment-of-copdandnbsp/Accessed November 29, 2016
   Google Scholar